CKD Bio Corp

CKD Bio Corp’s capital structure is characterized by a debt-to-equity ratio of 1.14, indicating a moderate reliance on debt financing. The company’s liquidity position is constrained, with a current ratio of 0.9 and negative net cash after subtracting total debt, suggesting potential short-term liquidity challenges. Despite a free cash flow of 5,397.62 billion KRW, the company’s operating cash flow is negative at -4,142.99 billion KRW, signaling operational inefficiencies. Profitability metrics are weak, with a return on equity of -2.27% and a return on assets of -0.96%, both significantly below the industry median for pharmaceutical companies. Gross profit of 28.78 billion KRW and operating income of 3.61 billion KRW reflect a narrow margin structure, which is a concern given the competitive nature of the pharmaceutical industry. The company’s revenue is distributed across three segments: API, Health Functional Food, and Botulinum Toxin. The API segment is the largest contributor, but the Health Functional Food and Botulinum Toxin segments are in early development stages, with limited revenue contribution. Geographically, the company is heavily concentrated in South Korea, with no material international revenue disclosed, exposing it to regional economic and regulatory risks. Growth prospects are mixed. The company reported a revenue of 160.07 billion KRW in the latest period, but net income is negative at -2.89 billion KRW. The outlook for the current fiscal year is uncertain, with no clear indication of revenue acceleration or margin expansion. The Botulinum Toxin segment, while in R&D, may offer long-term growth potential if commercialized successfully. Risk factors include liquidity constraints, negative operating cash flow, and a weak return on equity. The company’s dilution risk is currently low, with no near-term pressure from share issuance or convertible debt. However, the high debt-to-equity ratio and negative net cash position could necessitate future capital raising, which may dilute existing shareholders. Recent events include the continued development of the Botulinum Toxin segment and ongoing operations in the API and Health Functional Food segments. No material regulatory or legal events were disclosed in the latest filings.